ITGA7

Across TCGA pan-cancer cohorts, ITGA7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ITGA7 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ITGA7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ITGA7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where ITGA7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.633	0.213	.002	42	view →
GBM	DFS	Median	All	0.281	0.464	.009	16	view →
CCRCC	DFS	Median	III,IV	0.765	0.388	<.001	13	view →
LSCC	DFS	Quartile	II,III,IV	0.814	1.000	.018	3	view →
HNSC	OS	Tertile	All	0.949	1.000	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ITGA7–PDAC (DFS)

Open the PDAC breakdown →